

10th May, 2022

- | | |
|--|--|
| <p>(1) BSE Ltd.
Listing Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001
Scrip Code: 500087</p> <p>(3) SOCIETE DE LA BOURSE DE
LUXEMBERG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | <p>(2) National Stock Exchange of India Ltd.
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra (East), Mumbai - 400 051
Scrip Code: 500087</p> |
|--|--|

Dear Sir/Madam,

Sub: Audited Financial Results and Declaration of Dividend

The Board of the Directors of the Company at its meeting held today i.e. 10th May 2022, has *inter-alia* approved the Audited Financial Results (standalone and consolidated) for the quarter and year ended 31st March 2022.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the following:

- (1) Audited Financial Results (standalone and consolidated) for the quarter and year ended 31st March 2022;
- (2) Auditors' Report with unmodified opinion on the Audited Financial Results (standalone and consolidated) for the year ended 31st March 2022; and
- (3) Declaration from the Interim Chief Financial Officer under Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 confirming unmodified opinion of the statutory auditor on the standalone and consolidated audit report for the year ended 31st March 2022.

The Board of Directors also recommended the payment of a dividend of Rs. 5 per equity share (face value Rs.2 per equity share) for the year 2021-22. The dividend, upon approval by the shareholders, will be paid to shareholders within 30 days from the date of the Annual General Meeting.

The meeting of the Board of Directors of the Company commenced at 2.30 p.m. IST and is still in progress.

The above-mentioned documents will also be available on the Company's website www.cipla.com in the Investor Section.

Thanking you,
Yours faithfully,
For **Cipla Limited**

Rajendra Chopra
Company Secretary

Encl.: as above
Prepared by: Chirag Hotchandani

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2022

(₹ in Crores)

Particulars	Quarter ended			Year ended	
	31-03-2022	31-12-2021	31-03-2021	31-03-2022	31-03-2021
	Audited (Refer Note 11)	Unaudited	Audited (Refer Note 11)	Audited	Audited
1. Revenue from operations					
a) Revenue from sale of products	5,223.94	5,442.86	4,584.88	21,623.36	18,988.52
b) Other operating revenue	36.39	36.00	21.57	139.98	171.07
Total revenue from operations	5,260.33	5,478.86	4,606.45	21,763.34	19,159.59
2. Other income	64.02	91.29	60.13	280.91	265.99
3. Total income (1+2)	5,324.35	5,570.15	4,666.58	22,044.25	19,425.58
4. Expenses					
a) Cost of materials consumed	1,211.92	1,524.76	1,178.58	5,533.13	4,886.43
b) Purchases of stock-in-trade	747.04	716.63	530.86	3,687.16	2,658.17
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	187.74	(98.02)	112.98	(724.69)	(192.71)
d) Employee benefits expense	892.41	872.43	814.72	3,529.91	3,251.83
e) Finance costs	18.10	20.68	27.45	106.35	160.70
f) Depreciation, impairment and amortisation expense	290.31	247.47	285.19	1,051.95	1,067.66
g) Other expenses	1,471.50	1,232.09	1,173.07	5,185.05	4,303.44
Total expenses	4,819.02	4,516.04	4,122.85	18,368.86	16,135.52
5. Profit (+)/loss (-) before exceptional items and tax (3-4)	505.33	1,054.11	543.73	3,675.39	3,290.06
6. Exceptional item (refer note 8)	(57.50)	-	-	(182.12)	-
7. Profit (+)/loss (-) before tax (5-6)	447.83	1,054.11	543.73	3,493.27	3,290.06
8. Tax expense (net)					
a) Current tax	230.34	308.00	186.46	1,136.90	1,052.72
b) Deferred tax	(159.23)	(12.84)	(58.24)	(203.10)	(163.96)
Total tax expense	71.11	295.16	128.22	933.80	888.76
9. Net profit (+)/loss (-) after tax before share of associates (7-8)	376.72	758.95	415.51	2,559.47	2,401.30
10. Share of profit (+)/ loss (-) of associates	(6.02)	(2.07)	(4.00)	(12.82)	(12.79)
11. Net profit (+)/ loss (-) for the period/year (9+10)	370.70	756.88	411.51	2,546.65	2,388.51
12. Profit for the period/year attributable to					
a) Shareholders of the company	362.07	728.60	413.38	2,516.75	2,404.87
b) Non- controlling interest	8.63	28.28	(1.87)	29.90	(16.36)
13. Other comprehensive income/(loss) for the period/year					
a) (i) Items that will not be reclassified to profit or loss	119.19	4.70	(58.67)	127.02	(38.41)
(ii) Income tax on items that will not be reclassified to profit or loss	(13.51)	(1.18)	6.05	(15.48)	0.95
b) (i) Items that will be reclassified to profit or loss	252.83	(73.22)	(35.87)	272.75	203.18
(ii) Income tax on items that will be reclassified to profit or loss	12.49	(0.81)	4.30	(0.62)	(4.23)
Other comprehensive income/(loss) for the period/year	371.00	(70.51)	(84.19)	383.67	161.49
14. Total comprehensive income/(loss) for the period/year (11+13)	741.70	686.37	327.32	2,930.32	2,550.00
15. Total comprehensive income/(loss) attributable to					
a) Shareholders of the company	732.18	658.69	328.80	2,893.55	2,579.96
b) Non - controlling interest	9.52	27.68	(1.48)	36.77	(29.96)
16. Paid-up equity share capital (face value ₹ 2/- each) (Refer note 5)	161.36	161.36	161.29	161.36	161.29
17. Other equity				20,680.33	18,165.24
18. Earnings per share (face value ₹ 2/- each)					
a) Basic (₹)	*4.49	*9.03	*5.13	31.20	29.82
b) Diluted (₹)	*4.48	*9.02	*5.12	31.17	29.79
*Not Annualised					



Cipla Ltd.

Regd. office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400013, India.
P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-Mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380

Particulars	Segment information					(₹ in Crores)
	Quarter ended			Year ended		
	31-03-2022	31-12-2021	31-03-2021	31-03-2022	31-03-2021	
	Audited (Refer Note 11)	Unaudited	Audited (Refer Note 11)	Audited	Audited	
Segment wise revenue and results						
Segment revenue:						
a) Pharmaceuticals	5,175.95	5,377.28	4,543.67	21,351.27	18,878.24	
b) New ventures	110.59	127.09	93.68	531.51	401.27	
Total segment revenue	5,286.54	5,504.37	4,637.35	21,882.78	19,279.51	
Less : Inter segment revenue	26.21	25.51	30.90	119.44	119.92	
Total revenue from operations	5,260.33	5,478.86	4,606.45	21,763.34	19,159.59	
Segment result:						
Profit/(loss) before tax and interest from each segment						
a) Pharmaceuticals	587.17	1,098.12	632.65	3,943.73	3,633.71	
b) New ventures	(63.74)	(23.33)	(61.47)	(161.99)	(182.95)	
Total segment result	523.43	1,074.79	571.18	3,781.74	3,450.76	
Less: Finance costs	18.10	20.68	27.45	106.35	160.70	
Total Profit (+)/loss (-) before exceptional items and tax	505.33	1,054.11	543.73	3,675.39	3,290.06	
Less : Exceptional items - New ventures (refer note 8)	57.50	-	-	182.12	-	
Total Profit (+)/loss (-) before tax	447.83	1,054.11	543.73	3,493.27	3,290.06	

Segment assets and liabilities

As certain assets and liabilities are deployed interchangeably across segments, it is not practically possible to allocate those assets and liabilities to each segment. Hence, the details of assets and liabilities have not been disclosed in the above table.

Notes:

1. The financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.

2. The Company had received various notices of demand from the National Pharmaceutical Pricing Authority (NPPA), Government of India, on account of alleged overcharging in respect of certain drugs under the Drugs (Prices Control) Orders. The total demand against the Company as stated in NPPA public disclosure amounts to ₹ 3,703.40 Crore.

Out of the above, demand notices pertaining to a set of products being Norfloxacin, Ciprofloxacin, Salbutamol and Theophylline were challenged by the Company (i) in the Honourable Bombay High Court on the ground that bulk drugs contained in the said formulations are not amenable to price control, as they cannot be included in the ambit of price control based on the parameters contained in the Drug Policy, 1994 on which the DPCO, 1995 is based and (ii) in the Honourable Allahabad High Court on process followed for fixation of pricing norms. These Petitions were decided in favour of the Company and the matters were carried in appeal by the Union of India to the Honourable Supreme Court of India. The Honourable Supreme Court in its judgment of 1st August, 2003 remanded the said writ petitions to the Honourable Bombay High Court with directions that the Court will have to consider the petitions afresh, having due regard to the observations made by the Honourable Supreme Court in its judgment. On the Union of India filing transfer petitions, the Honourable Supreme Court ordered transfer of the said petitions to the Honourable Bombay High Court to it for being heard with the appeal filed against the Honourable Allahabad High Court order. Subsequently, in its order of 20th July, 2016 the Honourable Supreme Court recalled its transfer order and remanded the petitions to Honourable Bombay High Court for hearing. While remanding the matter to Honourable Bombay High Court, the Honourable Supreme Court directed Cipla to deposit 50% of the overcharged amount with the NPPA as stated in its order of 1st August, 2003 which at that point of time was ₹ 350.15 Crore. Complying with the directions passed by the Honourable Supreme Court, Cipla has deposited an amount of ₹ 175.08 Crore which has been received and acknowledged by NPPA. Furthermore, the Company has not received any further notices in these cases post such transfer of cases to Honourable Bombay High Court. Meanwhile, the Honourable Supreme Court vide its Order and Judgment dated 21st October, 2016, allowed the Appeals filed by the Government against the Judgment and Order of the Honourable Allahabad High Court regarding basis of fixation of retail prices. The said order was specific to fixation of retail prices without adhering to the formula/process laid down in DPCO, 1995. However, the grounds relating to inclusion of certain drugs within the span of price control continues to be sub-judice with the Honourable Bombay High Court.

The Honourable Bombay High Court had, in expectation of NPPA filing its counter-statement on status of each petitioner's compliance with the 2003 and 2016 Honourable Supreme Court orders (on deposit 50% of amount demanded), re-scheduled the hearing for 5th June, 2019, but the same was not listed on that date. The Company had filed amendment applications before the Honourable Bombay High Court to incorporate the effect of a ruling by the Honourable Supreme Court to adjust trade margins of 16% from outstanding demands as not accrued to the manufacturers and to re-calculate interest from date of non-payment of demand within the time period stated in each demand. The said amendment also places certain additional grounds on record. The Honourable Bombay High Court issued notice to Union of India and NPPA on the amendment applications and set 25th January, 2021 for further hearing but the case was not listed due to the COVID-19 lockdown and the next date is awaited.

The Company has been legally advised that it has a substantially strong case on the merits of the matter, especially under the guidelines/principles of interpretation of the Drug Policy enunciated by the Honourable Supreme Court. Although, the decision of Honourable Supreme Court dated 21st October, 2016 referred above was in favour of Union of India with respect to the appeals preferred by the Government challenging the Honourable Allahabad High Court order, basis the facts and legal advice on the matter sub-judice with the Honourable Bombay High Court, no provision is considered necessary in respect of the notices of demand received till date aggregating to ₹ 1,736.00 Crore. It may be noted that NPPA in its public disclosure has stated the total demand amount against the Company in relation to the above said molecules to be ₹ 3,281.31 Crore (after adjusting deposit of ₹ 175.08 Crore), however, the Company has not received any further notices beyond an aggregate amount of ₹ 1,736.00 Crore.

In addition, Company had made provision of ₹ 118.49 Crore as of 31st March, 2022 for products not part of the referenced writ proceedings. Further, no new recovery notices were received by the Company in the quarter, thus not requiring any fresh cases to be filed by the Company in that regard. Due to COVID-19, courts are hearing only urgent cases, hence the writs that are pending will be heard in due course.



Cipla Ltd.

Regd. office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400013, India.
P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-Mail contactus@cipla.com Corporate Identity Number L24239MH193SPLC002380

3. Consolidated statement of assets and liabilities :

(₹ in Crores)

Particulars	As at	As at
	31-03-2022	31-03-2021
	Audited	Audited
A. ASSETS		
1. Non-Current assets		
(a) Property, plant and equipment	4,838.79	4,618.14
(b) Right-of-use assets	325.61	338.13
(c) Capital work-in-progress	382.90	570.84
(d) Investment properties	61.42	121.75
(e) Goodwill	3,137.93	3,007.29
(f) Intangible assets	1,319.58	1,430.21
(g) Intangible assets under development	383.28	398.05
(h) Investment in associates	45.81	228.38
(i) Financial assets		
(i) Investments	309.82	195.30
(ii) Loans	0.04	0.04
(iii) Others financial assets	417.04	95.83
(j) Income tax assets (net)	483.62	468.16
(k) Deferred tax assets (net)	448.83	314.69
(l) Other non-current assets	218.91	155.57
Total non-current assets	12,373.58	11,942.38
2. Current assets		
(a) Inventories	5,350.24	4,669.18
(b) Financial assets		
(i) Investments	2,194.97	2,286.37
(ii) Trade receivables	3,424.44	3,445.68
(iii) Cash and cash equivalents	677.74	793.29
(iv) Bank balances other than cash and cash equivalents	1,250.74	607.94
(v) Loans	3.57	1.00
(vi) Other financial assets	898.39	483.24
(c) Other current assets	910.74	894.33
Total current assets	14,710.83	13,181.03
3. Assets classified as held-for-sale	16.71	28.48
Total assets	27,101.12	25,151.89
B. EQUITY and LIABILITIES		
1. Equity		
(a) Share capital	161.36	161.29
(b) Other equity	20,680.33	18,165.24
Equity attributable to owner	20,841.69	18,326.53
Non-controlling interest	275.69	259.06
Total equity	21,117.38	18,585.59
2. Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	416.24	1,202.75
(ii) Lease liabilities	158.28	197.89
(iii) Other financial liabilities	100.37	97.72
(b) Provisions	100.22	116.17
(c) Deferred tax liabilities (net)	243.96	296.61
(d) Other non-current liabilities	51.46	63.61
Total non-current liabilities	1,070.53	1,974.75
Current liabilities		
(a) Financial liabilities		
(i) Borrowings	407.90	552.81
(ii) Lease liabilities	73.36	60.96
(iii) Trade payables		
- Total outstanding dues of micro enterprises and small enterprises	175.12	69.33
- Total outstanding dues of creditors other than micro enterprises and small enterprises	2,332.98	1,997.49
(iv) Other financial liabilities	370.83	454.95
(b) Other current liabilities	311.06	359.22
(c) Provisions	1,221.00	1,078.32
(d) Income tax liabilities (net)	20.62	18.06
Total current liabilities	4,912.87	4,591.14
3. Liabilities directly associated with assets classified as held for sale	0.34	0.41
Total liabilities	5,983.74	6,566.30
Total equity and liabilities	27,101.12	25,151.89



Cipla Ltd.

Regd. office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400013, India.

P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-Mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380

4. Disclosure of statement of Cash Flows as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended 31st March, 2022

Particulars	Year ended	
	31-03-2022	31-03-2021
	Audited	Audited
Cash flow from operating activities		
Profit before exceptional items and tax	3,675.39	3,290.06
Adjustments for :		
Depreciation, impairment and amortisation expense	1,051.95	1,067.66
Interest expense	106.35	160.70
Unrealised foreign exchange (gain)/loss (net)	11.15	(8.64)
Share based payment expense	24.12	19.54
Allowances for credit loss (net)	(40.82)	39.48
Interest income on income tax refund	(17.75)	(7.04)
Interest income	(61.87)	(40.22)
Dividend income	(0.01)	(21.64)
Sundry balance written off (net)	(6.37)	(0.06)
Net gain on sale of current investment carried at fair value through profit or loss	(77.22)	(52.79)
Loss on liquidation of subsidiaries (net)	-	3.78
Net fair value (gain)/loss on financial instruments at fair value through profit or loss	(2.02)	(12.08)
Net gain on sale/disposal of property, plant and equipment	(8.68)	(3.01)
Rent income	(11.36)	(14.77)
Operating profit before working capital changes	4,642.86	4,420.97
Adjustments for working capital :		
Increase in inventories	(621.11)	(254.32)
Decrease in trade and other receivables	81.36	422.93
Increase in trade payables and other liabilities	362.29	203.05
Cash generated from operations	4,465.40	4,792.63
Income taxes paid (net of refunds)	(1,139.50)	(1,037.43)
Net cash flows from operating activities (a)	3,325.90	3,755.20
Cash flow from investing activities		
Purchase of property, plant and equipment (refer note (ii) below)	(544.11)	(629.66)
Purchase of intangible assets (including intangible asset under development)	(157.04)	(189.26)
Proceeds from sale of property, plant and equipment (refer note (ii) below)	16.40	22.05
Proceeds from sale of intangible assets	3.78	5.48
Proceeds from sale/liquidation of investments in subsidiaries	-	2.60
Investment in associates	(18.02)	(13.65)
Purchase of non-current investments	(0.05)	(40.00)
Sale/(Purchase) of current investments (net)	170.64	(1,204.98)
Receipt from sale of assets held for sale	14.98	-
Change in other bank balance and cash not available for immediate use	(1,416.82)	(416.72)
Interest received	46.99	40.55
Dividend received	0.01	21.64
Rent received	11.36	14.77
Net cash used in investing activities (b)	(1,871.88)	(2,387.18)
Cash flow from financing activities		
Proceeds from issue of equity shares (ESOSs)	0.07	0.05
Transaction with non-controlling interest (net)	(19.75)	(5.36)
Consideration paid to buyback of ESOP rights relating to subsidiary	(2.77)	(36.00)
Proceeds/ (Repayment) from current borrowings (net)	34.98	(41.87)
Payment of lease liabilities	(92.10)	(84.33)
Proceeds from non-current borrowings	-	70.49
Repayment of non-current borrowings	(1,041.21)	(1,021.75)
Interest paid	(75.66)	(120.74)
Dividend paid	(403.35)	-
Net cash used in financing activities (c)	(1,599.79)	(1,239.51)
Net (decrease) /increase in cash and cash equivalents (a+b+c)	(145.77)	128.51
Cash and cash equivalents at the beginning of the year	790.43	649.13
Exchange difference on translation of foreign currency cash and cash equivalents	13.45	12.79
Cash and cash equivalents at the end of the year	658.11	790.43

Notes:

- The above statement of cash flow has been prepared under the 'Indirect method' as set out in Indian Accounting Standard (Ind AS) 7- Statement of Cash Flows.
- Purchase and sale of property, plant and equipment represents additions and deletions to property, plant and equipment and investment properties adjusted for movement of capital work in progress, capital advances, capital creditors during the year.

Cipla Ltd.

Regd. office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400013, India.

P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-Mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380



5. The paid-up equity share capital stands increased to ₹ 161.36 Crore (80,68,14,036 equity shares of ₹ 2 each) upon allotment of 23,822 equity shares of ₹ 2 each pursuant to "ESOS 2013-A" during the quarter ended 31st March, 2022.
6. The Group continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it has impacted and will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of goodwill, investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the Group's financial results for the quarter and year ended 31st March, 2022.
7. The Board at its meeting held on 25th January, 2022 had approved the restructuring/transfer of:
- a) the India based US business undertaking to Cipla Pharma and Life Sciences Limited (formerly known as Cipla BioTec Limited), a wholly owned subsidiary of the Company; and
 - b) the Consumer business Undertaking to Cipla Health Limited, a wholly owned subsidiary of the Company, as a going concern on a slump sale basis through a Business Transfer Agreement ("BTA"). The Company is currently in the process of completing the regulatory and legal process for transfer as on 31st March 2022. Since the transactions are with parties under common control, there is no impact on the consolidated financial results for the period / year ended 31st March 2022.
8. During the current quarter, Avenue Therapeutics, Inc's ('Avenue'), an associate Company, announced that it had received an appeal denial letter from the USFDA's Office of New Drugs regarding Avenue's formal dispute resolution request for Tramadol IV NDA. Basis the same and change in the market dynamics in relation to Tramadol IV NDA, the management carried out an impairment assessment of their investment in Avenue. Accordingly, an additional impairment charge amounting to ₹ 57.50 crore has been recorded as an exceptional item in consolidated financial results for the quarter and ₹ 182.12 crores for the year ended 31st March 2022.
9. The audited standalone financial results for the quarter and year ended 31st March, 2022 are available on the Company's website i.e. www.cipla.com under Investor Information section and on the stock exchange websites i.e. www.bseindia.com and www.nseindia.com.
10. The figures of the previous year/period have been regrouped/recast to render them comparable with the figures of the current period.
11. The figures for the quarter ended 31st March, 2022 and 31st March, 2021 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.
12. The Board of Directors of the Company at its meeting held on 10th May, 2022 has recommended a final dividend of ₹ 5/- per equity share (face value ₹ 2 each) for the financial year ended 31st March, 2022. The dividend is subject to approval at the ensuing annual general meeting of the Company.
13. The above results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 10th May, 2022. These results have been subjected to audit by statutory auditors who have expressed an unqualified opinion.

By order of the Board
For CIPLA LIMITED

Mumbai
10th May, 2022

Umang Vohra
Managing Director and Global Chief Executive Officer



Cipla Ltd.

Regd. office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400013, India.

P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-Mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380

Walker Chandiook & Co LLP

11th Floor, Tower II,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India
T +91 22 6626 2699
F +91 22 6626 2601

Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Cipla Limited

Opinion

1. We have audited the accompanying consolidated annual financial results ('the Statement') of **Cipla Limited** ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associates for the year ended **31 March 2022**, attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of other auditors on separate audited financial statements/financial information of the subsidiaries and associates, as referred to in paragraph 11 below, the Statement:
 - (i) includes the annual financial results of the entities listed in Annexure 1;
 - (ii) presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations, and
 - (iii) gives a true and fair view in conformity with the applicable Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 ('the Act') read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the consolidated net profit after tax and other comprehensive income and other financial information of the Group and its associates, for the year ended 31 March 2022.



Cipla Limited

Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Statement section of our report. We are independent of the Group and its associates, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act, and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us together with the audit evidence obtained by the other auditors in terms of their reports referred to in paragraph 11 of the Other Matter section below, is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Statement

4. The Statement, which is the responsibility of the Holding Company's management and has been approved by the Holding Company's Board of Directors, has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the consolidated net profit or loss and other comprehensive income, and other financial information of the Group including its associates in accordance with the Ind AS prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Holding Company's Board of Directors is also responsible for ensuring accuracy of records including financial information considered necessary for the preparation of the Statement. Further, in terms of the provisions of the Act, the respective Board of Directors of the companies included in the Group and its associates, covered under the Act, are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding of the assets of the Group, and its associates, and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively, for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results, that give a true and fair view and are free from material misstatement, whether due to fraud or error. These financial results have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.
5. In preparing the Statement, the respective Board of Directors of the companies included in the Group and of its associates, are responsible for assessing the ability of the Group and of its associates, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting, unless the respective Board of Directors/ management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.
6. The respective Board of Directors of the companies included in the Group and of its associates, are responsible for overseeing the financial reporting process of the companies included in the Group and of its associates.



Cipla Limited

Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Auditor's Responsibilities for the Audit of the Statement

7. Our objectives is to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act will always detect a material misstatement, when it exists. Misstatements can arise from fraud or error, and are considered material if, individually, or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
8. As part of an audit in accordance with the Standards on Auditing specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls system with reference to financial statements in place and the operating effectiveness of such controls.
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
 - Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates, to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
 - Obtain sufficient appropriate audit evidence regarding the financial results statements of the entities within the Group, and its associates, to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement, of which we are the independent auditors. For the other entities included in the Statement, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.



Cipla Limited

Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

9. We communicate with those charged with governance of the Holding Company and such other entities included in the Statement, of which we are the independent auditors, regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

11. We did not audit the annual financial statements/ financial information of 37 subsidiaries included in the Statement, whose financial information (prior to consolidation adjustments), reflects total assets of ₹ 10,730.48 crore as at 31 March 2022, total revenues of ₹ 4,522.83 crore, total net profit after tax of ₹ 154.93 crore total comprehensive income of ₹ 319.25 crore, and cash flows (net) of ₹ 19.94 crore for the year ended on that date, as considered in the Statement. The Statement also includes the Group's share of net loss (including other comprehensive income) of ₹ (2.36) crore for the year ended 31 March 2022, in respect of an associate, whose annual financial statements have not been audited by us. These annual financial statements have been audited by other auditors whose audit reports have been furnished to us by the management, and our opinion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associates is based solely on the audit reports of such other auditors, and the procedures performed by us as stated in paragraph 8 above.

Further, of these subsidiaries and associates, 33 subsidiaries and an associate are located outside India, whose annual financial statements have been prepared in accordance with accounting principles generally accepted in their respective countries, and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Holding Company's management has converted the financial statements such subsidiaries and associates from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have audited these conversion adjustments made by the Holding Company's management. Our opinion, in so far as it relates to the balances and affairs of these subsidiaries and an associate, is based on the audit report of other auditors and the conversion adjustments prepared by the management of the Holding Company and audited by us.

Our opinion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

12. The Statement also includes the Group's share of net loss (including other comprehensive income) of ₹ (10.46) crore for the year ended 31 March 2022, in respect of 4 associates, based on their annual financial information, which have not been audited by their auditors. Those financial information have been furnished to us by the Holding Company's management. Our opinion, in so far as it relates to the amounts and disclosures included in respect of aforesaid associates, is based solely on such unaudited financial information. In our opinion, and according to the information and explanations given to us by the management, these financial statements/ financial information are not material to the Group.

Our opinion is not modified in respect of this matters with respect to our reliance on the financial statements/ financial information certified by the Board of Directors.



Cipla Limited

Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

13. The Statement includes the consolidated financial results for the quarter ended 31 March 2022, being the balancing figures between the audited consolidated figures in respect of the full financial year and the published unaudited year-to-date consolidated figures up to the third quarter of the current financial year, which were subject to limited review by us.

For **Walker Chandio & Co LLP**
Chartered Accountants
Firm Registration No:001076N/N500013


Ashish Gupta
Partner
Membership No:504662



UDIN:22504662AISJHE1410

Place : Mumbai
Date : 10 May 2022

Cipla Limited

Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Annexure 1

List of entities included in the Statement

I) Subsidiaries:

1. Meditab Specialities Limited, India
2. Goldencross Pharma Limited, India
3. Cipla Pharma and Life Sciences Limited, India (formerly known as Cipla BioTec Limited)
4. Jay Precision Pharmaceuticals Private Limited, India
5. Cipla Health Limited, India
6. Medispray Laboratories Private Limited, India
7. Sitec Labs Limited, India
8. Cipla Digital Health Limited, India (incorporated on 25 February 2022)
9. Cipla Medpro South Africa (Pty) Limited, South Africa
10. Cipla Holding B.V., Netherlands
11. Cipla (EU) Limited, United Kingdom
12. Saba Investment Limited, United Arab Emirates
13. Cipla (UK) Limited, United Kingdom, (liquidated w.e.f. 5 March 2021)
14. Cipla Australia Pty Limited, Australia
15. Cipla USA Inc., United States of America
16. Meditab Holdings Limited, Mauritius
17. Cipla Kenya Limited, Kenya
18. Cipla Malaysia Sdn. Bhd., Malaysia
19. Cipla Europe NV, Belgium
20. Cipla Quality Chemical Industries Limited, Uganda
21. Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda., Brazil
22. Inyanga Trading 386 (Pty) Limited, South Africa (Dissolved w.e.f. 10 December 2021)
23. Cipla Medpro Holdings (Pty) Limited, South Africa (under liquidation)
24. Cape to Cairo Exports (Pty) Limited, South Africa (Deregistered w.e.f. 27 August 2020)
25. Cipla Dibcare (Pty) Limited, South Africa (under liquidation)
26. Cipla Medpro Manufacturing (Pty) Limited, South Africa (formerly known as Cipla Life Sciences (Pty) Limited)
27. Cipla-Medpro (Pty) Limited, South Africa
28. Cipla-Medpro Distribution Centre (Pty) Limited, South Africa
29. Cipla Medpro Botswana (Pty) Limited, South Africa
30. Cipla Algérie, Algeria
31. Cipla Biotec South Africa (Pty) Limited, South Africa (deregistered w.e.f. 3 February 2022)
32. Cipla Select (Pty) Limited, South Africa (formerly known as Cipla OLTP (Pty) Limited)
33. Medpro Pharmaceutica (Pty) Limited, South Africa
34. Cipla Medica Pharmaceutical and Chemical Industries Limited, Yemen
35. Cipla (Mauritius) Limited, Mauritius (liquidated w.e.f. 17 May 2020)
36. Breathe Free Lanka (Private) Limited, Sri Lanka
37. Cipla Maroc SA, Morocco
38. Cipla Middle East Pharmaceuticals FZ-LLC, United Arab Emirates
39. Quality Chemicals Limited, Uganda (ceased to be a subsidiary from 19 August 2020)
40. Cipla Philippines Inc., Philippines
41. InvaGen Pharmaceuticals Inc., United States of America
42. Exelan Pharmaceuticals, Inc., United States of America



Cipla Limited

Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Annexure 1 (Contd)

43. Anmaraté (Pty) Limited, South Africa (ceased to be a subsidiary from 19 August 2020)
44. Cipla Technologies LLC, United States of America
45. Cipla Gulf FZ-LLC, United Arab Emirates
46. Mirren (Pty) Limited, South Africa
47. Madison Pharmaceuticals Inc., United States of America
48. Cipla Colombia SAS, Colombia
49. Cipla (China) Pharmaceutical Co., Ltd., China
50. Cipla Health Employees Stock Option Trust, India
51. Cipla Employee Stock Option Trust, India (Deregistered)
52. Cipla (Jiangsu) Pharmaceutical Co., Ltd., China
53. Cipla Pharmaceuticals Limited, India
54. Cipla Therapeutics Inc, United States of America

II) Associates:

1. Stempeutics Research Private Limited, India
2. Avenue Therapeutics Inc., United States of America (As at 31 March 2022, the fully diluted stake is 25.93%)
3. Brandmed (Pty) Limited, South Africa
4. AMPSolar Power Systems Private Limited – (Share of loss/profit not required to be considered)
5. AMP Energy Green Eleven Private Limited (acquired 32.49 % on fully diluted basis from 8 February 2022) - (Share of loss/profit not required to be considered)
6. Clean Max Auriga Power LLP (acquired 33% stake effective from 14 December 2021) – (Share of loss/profit not required to be considered)
7. GoAptiv Private Limited
8. Iconphygital Private Limited (Wholly owned subsidiary of GoAptiv Private Limited)



STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2022

(₹ in Crores)

Particulars	Quarter ended			Year ended	
	31-03-2022	31-12-2021	31-03-2021	31-03-2022	31-03-2021
	Audited (Refer Note 6)	Unaudited	Audited (Refer Note 6)	Audited	Audited
A. Continuing Operations :					
1. Revenue from operations					
a) Revenue from sale of products	2,882.08	3,265.34	2,587.51	12,827.29	11,060.17
b) Other operating revenue	64.53	71.02	56.69	264.50	242.54
Total revenue from operations	2,946.61	3,336.36	2,644.20	13,091.79	11,302.71
2. Other income	316.31	73.00	49.33	666.70	230.28
3. Total income (1+2)	3,262.92	3,409.36	2,693.53	13,758.49	11,532.99
4. Expenses					
a) Cost of materials consumed	369.54	855.21	394.21	2,767.79	2,249.35
b) Purchases of stock-in-trade	526.94	578.40	349.66	2,850.85	1,847.85
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	405.69	(165.09)	172.91	(528.40)	6.41
d) Employee benefits expense	429.00	431.23	413.75	1,729.16	1,703.58
e) Finance costs	5.78	5.55	8.84	26.93	45.07
f) Depreciation, impairment and amortisation expense	116.82	112.86	117.75	460.01	468.62
g) Other expenses	827.79	728.55	675.42	2,905.92	2,428.11
Total expenses	2,681.56	2,546.71	2,132.54	10,212.26	8,748.99
5. Profit (+)/loss (-) before tax from continuing operations (3-4)	581.36	862.65	560.99	3,546.23	2,784.00
6. Tax expense (net)					
a) Current tax	108.56	239.44	132.05	887.24	756.27
b) Deferred tax	(3.50)	(24.62)	9.28	(30.40)	(16.92)
Total tax expense	105.06	214.82	141.33	856.84	739.35
7. Net profit (+)/loss (-) after tax for the period/year from continuing operations (5-6)	476.30	647.83	419.66	2,689.39	2,044.65
B. Discontinuing/Restructuring Operations : (refer note 5)					
8. Profit (+)/loss (-) before tax from Discontinuing/Restructuring operations	236.09	110.83	(7.81)	358.85	566.66
9. Tax expense from Discontinuing/Restructuring operations	59.43	27.83	(1.56)	90.31	143.03
10. Net profit (+)/loss (-) after tax for the period/year from Discontinuing/Restructuring operations (8-9)	176.66	83.00	(6.25)	268.54	423.63
11. Net profit (+)/loss (-) for the period/year (7+10)	652.96	730.83	413.41	2,957.93	2,468.28
12. Other comprehensive income/(loss) for the period/year					
I . In respect of continuing operations:					
a) (i) Items that will not be reclassified to profit or loss	8.81	4.50	(0.57)	16.78	17.56
(ii) Income tax on items that will not be reclassified to profit or loss	(2.21)	(1.13)	0.14	(4.22)	(4.42)
b) (i) Items that will be reclassified to profit or loss	(40.11)	6.01	(29.05)	(9.38)	37.08
(ii) Income tax on items that will be reclassified to profit or loss	10.10	(1.51)	7.50	2.37	(9.33)
II . In respect of Discontinuing/Restructuring operations: (refer note 5)					
a) (i) Items that will not be reclassified to profit or loss	0.38	0.20	(0.02)	0.73	0.76
(ii) Income tax on items that will not be reclassified to profit or loss	(0.10)	(0.05)	0.01	(0.18)	(0.19)
Other comprehensive income/(loss) for the period/year	(23.13)	8.02	(21.99)	6.10	41.46
13. Total comprehensive income/(loss) for the period/year (11+12)	629.83	738.85	391.42	2,964.03	2,509.74
14. Paid-up equity share capital (face value ₹ 2/- each) (Refer note 3)	161.36	161.36	161.29	161.36	161.29
15. Other equity				22,352.19	19,766.27
16. Earnings per share from continuing operations (face value ₹ 2/- each)					
a) Basic (₹)	*5.90	*8.03	*5.21	33.34	25.36
b) Diluted (₹)	*5.90	*8.02	*5.20	33.30	25.32
17. Earnings per share from Discontinuing/Restructuring operations (face value ₹ 2/- each)					
a) Basic (₹)	*2.19	*1.03	*(0.08)	3.33	5.25
b) Diluted (₹)	*2.19	*1.03	*(0.08)	3.33	5.25
18. Earnings per share for total operations (face value ₹ 2/- each)					
a) Basic (₹)	*8.09	*9.06	*5.13	36.67	30.61
b) Diluted (₹)	*8.09	*9.05	*5.12	36.63	30.57
*Not Annualised					



Standalone statement of assets and liabilities :-

(₹ in Crores)

Particulars	As at	As at
	31-03-2022	31-03-2021
	Audited	Audited
A. ASSETS		
1. Non-current assets		
(a) Property, plant and equipment	3,049.56	3,569.27
(b) Right-of-use assets	62.17	103.88
(c) Capital work-in-progress	169.22	275.04
(d) Investment properties	63.35	123.79
(e) Intangible assets	215.96	269.51
(f) Intangible assets under development	44.62	80.07
(g) Financial assets		
(i) Investments	8,934.88	7,720.99
(ii) Others financial assets	368.88	83.57
(h) Income tax assets (net)	377.12	401.31
(i) Other non-current assets	138.66	144.13
Total non-current assets	13,424.42	12,771.56
2. Current assets		
(a) Inventories	3,199.05	3,085.81
(b) Financial assets		
(i) Investments	2,038.80	2,004.84
(ii) Trade receivables	1,939.62	3,035.37
(iii) Cash and cash equivalents	177.29	294.72
(iv) Bank balances other than cash and cash equivalents	1,250.74	580.08
(v) Loans	0.89	0.96
(vi) Other financial assets	856.63	475.04
(c) Other current assets	674.13	713.93
Total current assets	10,137.15	10,190.75
3. Assets classified as held-for-sale/transfer (refer note 5)	1,887.48	1.43
Total assets	25,449.05	22,963.74
B. EQUITY and LIABILITIES		
1. Equity		
(a) Share capital	161.36	161.29
(b) Other equity	22,352.19	19,766.27
Total equity	22,513.55	19,927.56
2. Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Lease liabilities	11.59	29.46
(ii) Other financial liabilities	53.13	56.01
(b) Provisions	78.92	95.97
(c) Deferred tax liabilities (net)	55.96	104.91
(d) Other non-current liabilities	7.34	57.89
Total non-current liabilities	206.94	344.24
Current liabilities		
(a) Financial liabilities		
(i) Lease liabilities	7.33	22.66
(ii) Trade payables		
- Total outstanding dues of micro enterprises and small enterprises	146.52	49.17
- Total outstanding dues of creditors other than micro enterprises and small enterprises	1,232.41	1,446.32
(iii) Other financial liabilities	186.16	236.15
(b) Other current liabilities	201.28	312.51
(c) Provisions	630.79	620.56
(d) Income tax liabilities (net)	-	4.57
Total current liabilities	2,404.49	2,691.94
3. Liabilities directly associated with assets classified as held for sale/transfer (refer note 5)	324.07	-
Total liabilities	2,935.50	3,036.18
Total equity and liabilities	25,449.05	22,963.74



Disclosure of statement of Cash Flows as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended 31st March, 2022

Particulars	Year ended	
	31-03-2022	31-03-2021
	Audited	Audited
Cash flow from operating activities		
Profit before tax from:		
Continuing operations	3,546.23	2,784.00
Discontinuing/Restructuring operations (refer note 5)	358.85	566.66
Adjustments for :		
Depreciation, impairment and amortisation expense	546.62	556.11
Interest expense	26.93	45.07
Unrealised foreign exchange gain (net)	(1.45)	(20.58)
Share based payment expense	19.68	14.78
Allowances for credit loss (net)	14.19	19.65
Provision for diminution in value of investment	-	10.88
Interest income	(57.25)	(36.42)
Interest income on income tax refund	(15.64)	-
Dividend income	(403.32)	-
Sundry balances written off (net)	24.05	8.10
Net gain on sale of current investments carried at fair value through profit or loss	(64.00)	(47.67)
Fair value gain on financial instruments at fair value through profit or loss	(3.23)	(10.12)
Net gain on sale/disposal of property, plant and equipment	(0.72)	(3.48)
Rent income	(12.60)	(15.91)
Operating profit before working capital changes	3,978.34	3,871.07
Adjustments for working capital:		
Increase in inventories	(433.56)	(64.45)
Decrease in trade and other receivables	225.70	519.50
(Decrease)/ Increase in trade payables and other liabilities	(63.02)	86.14
Cash generated from operations	3,707.46	4,412.26
Income taxes paid (net of refunds)	(934.03)	(951.95)
Net cash flows generated from operating activities (a)	2,773.43	3,460.31
Cash flow from investing activities		
Purchase of property, plant and equipment (refer note (ii) below)	(305.04)	(370.46)
Purchase of intangible assets (including intangible asset under development)	(26.64)	(146.51)
Proceeds from sale of property, plant and equipment (refer note (ii) below)	11.18	12.33
Investment in associates	(15.43)	(9.00)
Purchase of non current investment	-	(40.00)
Investments in subsidiaries	(1,173.43)	(1,360.21)
(Purchase)/Sale of current investments (net)	33.27	(1,112.61)
Change in other bank balance and cash not available for immediate use	(1,444.21)	(388.48)
Interest received	40.65	38.58
Dividend received from subsidiaries	403.32	-
Rent received	12.60	15.91
Net cash flow used in investing activities (b)	(2,463.73)	(3,360.45)
Cash flow from financing activities		
Proceeds from issue of equity shares (ESOs)	0.07	0.05
Repayment from current borrowings (net)	-	(6.06)
Interest paid	(3.84)	(34.01)
Payment of lease liabilities	(19.60)	(25.78)
Dividend paid	(403.35)	-
Net cash flow used in financing activities (c)	(426.72)	(65.80)
Net increase in cash and cash equivalents (a+b+c)	(117.02)	34.06
Cash and cash equivalents at the beginning of the year	294.72	261.54
Exchange difference on translation of foreign currency cash and cash equivalents	(0.41)	(0.88)
Cash and cash equivalents at the end of the year	177.29	294.72

Notes:

i. The above statement of cash flow has been prepared under the 'Indirect method' as set out in Indian Accounting Standard (Ind AS) 7-Statement of Cash Flows.

ii. Purchase and sale of property, plant and equipment represents additions and deletions to property, plant and equipment and investment properties adjusted for movement of capital work in progress, capital advances, capital creditors during the year.



1. The financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.

2. The Company had received various notices of demand from the National Pharmaceutical Pricing Authority (NPPA), Government of India, on account of alleged overcharging in respect of certain drugs under the Drugs (Prices Control) Orders. The total demand against the Company as stated in NPPA public disclosure amounts to ₹ 3,703.40 Crore.

Out of the above, demand notices pertaining to a set of products being Norfloxacin, Ciprofloxacin, Salbutamol and Theophylline were challenged by the Company (i) in the Honourable Bombay High Court on the ground that bulk drugs contained in the said formulations are not amenable to price control, as they cannot be included in the ambit of price control based on the parameters contained in the Drug Policy, 1994 on which the DPCO, 1995 is based and (ii) in the Honourable Allahabad High Court on process followed for fixation of pricing norms. These Petitions were decided in favour of the Company and the matters were carried in appeal by the Union of India to the Honourable Supreme Court of India. The Honourable Supreme Court in its judgment of 1st August, 2003 remanded the said writ petitions to the Honourable Bombay High Court with directions that the Court will have to consider the petitions afresh, having due regard to the observations made by the Honourable Supreme Court in its judgment. On the Union of India filing transfer petitions, the Honourable Supreme Court ordered transfer of the said petitions to the Honourable Bombay High Court to it for being heard with the appeal filed against the Honourable Allahabad High Court order. Subsequently, in its order of 20th July, 2016 the Honourable Supreme Court recalled its transfer order and remanded the petitions to Honourable Bombay High Court for hearing. While remanding the matter to Honourable Bombay High Court, the Honourable Supreme Court directed Cipla to deposit 50% of the overcharged amount with the NPPA as stated in its order of 1st August, 2003 which at that point of time was ₹ 350.15 Crore. Complying with the directions passed by the Honourable Supreme Court, Cipla has deposited an amount of ₹ 175.08 Crore which has been received and acknowledged by NPPA. Furthermore, the Company has not received any further notices in these cases post such transfer of cases to Honourable Bombay High Court. Meanwhile, the Honourable Supreme Court vide its Order and Judgment dated 21st October, 2016, allowed the Appeals filed by the Government against the Judgment and Order of the Honourable Allahabad High Court regarding basis of fixation of retail prices. The said order was specific to fixation of retail prices without adhering to the formula/process laid down in DPCO, 1995. However, the grounds relating to inclusion of certain drugs within the span of price control continues to be sub-judice with the Honourable Bombay High Court.

The Honourable Bombay High Court had, in expectation of NPPA filing its counter-statement on status of each petitioner's compliance with the 2003 and 2016 Honourable Supreme Court orders (on deposit 50% of amount demanded), re-scheduled the hearing for 5th June, 2019, but the same was not listed on that date.

The Company had filed amendment applications before the Honourable Bombay High Court to incorporate the effect of a ruling by the Honourable Supreme Court to adjust trade margins of 16% from outstanding demands as not accrued to the manufacturers and to re-calculate interest from date of non-payment of demand within the time period stated in each demand. The said amendment also places certain additional grounds on record. The Honourable Bombay High Court issued notice to Union of India and NPPA on the amendment applications and set 25th January, 2021 for further hearing but the case was not listed due to the COVID-19 lockdown and the next date is awaited.

The Company has been legally advised that it has a substantially strong case on the merits of the matter, especially under the guidelines/principles of interpretation of the Drug Policy enunciated by the Honourable Supreme Court. Although, the decision of Honourable Supreme Court dated 21st October, 2016 referred above was in favour of Union of India with respect to the appeals preferred by the Government challenging the Honourable Allahabad High Court order, basis the facts and legal advice on the matter sub-judice with the Honourable Bombay High Court, no provision is considered necessary in respect of the notices of demand received till date aggregating to ₹ 1,736.00 Crore. It may be noted that NPPA in its public disclosure has stated the total demand amount against the Company in relation to the above said molecules to be ₹ 3,281.31 Crore (after adjusting deposit of ₹ 175.08 Crore), however, the Company has not received any further notices beyond an aggregate amount of ₹ 1,736.00 Crore.

In addition, Company had made provision of ₹ 118.49 Crore as of 31st March, 2022 for products not part of the referenced writ proceedings. Further, no new recovery notices were received by the Company in the quarter, thus not requiring any fresh cases to be filed by the Company in that regard. Due to COVID-19, courts are hearing only urgent cases, hence the writs that are pending will be heard in due course.

3. The paid-up equity share capital stands increased to ₹ 161.36 Crore (80,68,14,036 equity shares of ₹ 2 each) upon allotment of 23,822 equity shares of ₹ 2 each pursuant to "ESOS 2013-A" during the quarter ended 31st March, 2022.



4. The Company continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it has impacted and will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the Company's financial results for the quarter and year ended 31st March, 2022.

5. The Board at its meeting held on 25th January, 2022 had approved the restructuring/ transfer of :

- the India based US business undertaking to Cipla Pharma and Life Sciences Limited (formerly known as Cipla BioTec Limited), a wholly owned subsidiary of the Company; and
- the Consumer business undertaking to Cipla Health Limited, a wholly owned subsidiary of the Company, as a going concern on a slump sale basis through a Business Transfer Agreement ("BTA"). The Company is currently in the process of completing the regulatory and legal process for transfer as on 31st March 2022. Accordingly, the disclosures have been made in the standalone financial results for all the periods presented.

Key financial information of Discontinuing/Restructuring operations :

(₹ in Crores)

Particulars	Quarter ended			Year ended	
	31-03-2022	31-12-2021	31-03-2021	31-03-2022	31-03-2021
Total revenue from operations	852.86	618.43	588.92	2,614.91	2,597.87
Total expenses	616.77	507.60	596.73	2,256.06	2,031.21
Profit (+)/loss (-) before tax	236.09	110.83	(7.81)	358.85	566.66
Total tax expense	59.43	27.83	(1.56)	90.31	143.03
Net profit (+)/loss (-) for the period/year	176.66	83.00	(6.25)	268.54	423.63

6. The figures for the quarter ended 31st March, 2022 and 31st March, 2021 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine month of the relevant financial year.

7. The figures of the previous year/period have been regrouped/recast to render them comparable with the figures of the current period.

8. The Board of Directors of the Company at its meeting held on 10th May, 2022 has recommended a final dividend of ₹ 5/- per equity share (face value ₹ 2 each) for the financial year ended 31st March, 2022. The dividend is subject to approval at the ensuing annual general meeting of the Company.

9. The above results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 10th May, 2022. These results have been subjected to audit by statutory auditors who expressed an unqualified opinion.

By order of the Board
For CIPLA LIMITED

Mumbai
10th May, 2022

Umang Vohra
Managing Director and Global Chief Executive Officer



Walker Chandiook & Co LLP

11th Floor, Tower II,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India
T +91 22 6626 2699
F +91 22 6626 2601

Independent Auditor's Report on Standalone Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Cipla Limited

Opinion

1. We have audited the accompanying standalone annual financial results ('the Statement') of **Cipla Limited** ('the Company') for the year ended **31 March 2022**, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - (i) presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations, and
 - (ii) gives a true and fair view in conformity with the applicable Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 ('the Act'), read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the standalone net profit after tax and other comprehensive income and other financial information of the Company for the year ended 31 March 2022.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Statement section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.



Cipla Limited

Independent Auditor's Report on Standalone Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Responsibilities of Management and Those Charged with Governance for the Statement

4. This Statement has been prepared on the basis of the standalone annual financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit/loss and other comprehensive income and other financial information of the Company in accordance with the Ind AS specified under section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.
5. In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Statement

7. Our objectives is to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
8. As part of an audit in accordance with the Standards on Auditing, specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place an adequate internal financial controls with reference to financial statements and the operating effectiveness of such controls.



Cipla Limited

Independent Auditor's Report on Standalone Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
 - Conclude on the appropriateness of the management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

11. The Statement includes the financial results for the quarter ended 31 March 2022, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subject to limited review by us.

For **Walker Chandio & Co LLP**
Chartered Accountants
Firm Registration No:001076N/N500013


Ashish Gupta
Partner
Membership No:504662



UDIN:22504662AISIU3796

Place: Mumbai
Date: 10 May 2022

10th May, 2022

- | | |
|--|--|
| <p>(1) BSE Ltd.
Listing Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001
Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Ltd.
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra (East), Mumbai - 400 051
Scrip Code: 500087</p> |
| <p>(3) SOCIETE DE LA BOURSE DE
LUXEMBERG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | |

Dear Sir/Madam,

Sub: Declaration pursuant to regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

We, hereby confirm and declare that the Statutory Auditors of the Company i.e. Walker Chandiook & Co LLP, Chartered Accountants, have issued the audit report on Standalone and Consolidated Financial Results of the Company for the year ended 31st March 2022 with unmodified opinion.

Thanking you,

Yours faithfully,
For **Cipla Limited**

Dinesh Jain
Interim Chief Financial Officer